Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Stevens johnson syndrome & toxic epidermal necrolysis

2,110 views

Published on

Stevens johnson syndrome & toxic epidermal necrolysis
Presented by Jintana Chataroopwijit, MD.
September23, 2016

Published in: Health & Medicine
  • Be the first to comment

Stevens johnson syndrome & toxic epidermal necrolysis

  1. 1. STEVENS-JOHNSON SYNDROME TOXIC EPIDERMAL NECROLYSIS Jintana Chataroopwijit 23 September 2016
  2. 2. INTRODUCTION ➤ Severe cutaneous adverse reaction (SCAR) ➤ Immune-complex-mediated hypersensitivity complex
  3. 3. CLASSIFICATION Body surface area detachment 1. Steven-Johnson syndrome : less than 10% 2. Overlapping Steven-Johnson syndrome/toxic epidermal necrolysis 3. Toxic epidermal necrolysis : more than 30%
  4. 4. EPIDERMIOLGY ➤ Steven-Johnson syndrome : 1-6 cases per million per year ➤ Toxic epidermal necrolysis : 1-2 cases per million per year ➤ Primarily male, AIDS patients Autoimmunity Review 7 (2008) 598-608
  5. 5. INCIDENCE
  6. 6. ETIOLOGY ➤ Drug-induced ➤ Infectious ➤ Malignancy related ➤ Idiopathic International Journal of Pharmacology Reasearch volume4 Issue4 (2014
  7. 7. ETIOLOGY : DRUG-INDUCED Autoimmunity Review 7 (2008) 598-608
  8. 8. Alden score
  9. 9. ETIOLOGY : INFECTIOUS International Journal of Pharmacology Reasearch volume4 Issue4 (2014) ➤ Herpes simplex virus ➤ AIDS ➤ Coxsackie viral infection ➤ Influenza ➤ Hepatitis ➤ Mumps ➤ Epstein-Barr virus ➤ Enteroviruses ➤ Group A beta-hemolytic streptococci ➤ Diphteria ➤ Brucellosis ➤ Lymphogranuloma venereum ➤ Mycobacteria ➤ Mycoplasma pneumoniae ➤ Rickettsial infections ➤ Tularemia ➤ Typhoid
  10. 10. GENETIC SUSCEPTIBILITY J Allergy Clin Immonol (2012) vol.136 no.2
  11. 11. GENETIC SUSCEPTIBILITY J Allergy Clin Immonol (2012) vol.136 no.2
  12. 12. ETIOLOGY ➤ Malignancy related ➤ Photo-induced ➤ Post vaccination ➤ Idiopathic Autoimmunity Review 7 (2008) 598-608
  13. 13. PATHOGENESIS ➤ Not fully understood ➤ Immune-mediated Autoimmunity Review 7 (2008) 598-608
  14. 14. IMMUNOHISTOCHEMICAL CHARACTERISTICS ➤ Detection of activated T cell in lesion skin ➤ Predominance of CD4+ T cell in dermis and CD8+ in epidermis Autoimmunity Review 7 (2008) 598-608
  15. 15. HISTOLOGY OF DISEASE
  16. 16. PATHOGENESIS
  17. 17. J Allergy Clin Immonol (2012) vol.136 no.2
  18. 18. IMMUNOPATHOLOGY ➤ Two pathways leading to apoptosis cell death ➤ Ligation of Fas and FasL ➤ Release of Perforin and GranzymeB Autoimmunity Review 7 (2008) 598-608
  19. 19. FAS/FAS LIGAND ➤ Fas ➤ Skin homeostasis ➤ Expression in normal keratinocyte at basal membrane and first suprabasal cell layer ➤ In TEN : stain positive for FasL in perivascular and junctional dermis in skin-infiltrating lymphocyte ➤ Ligation of Fas on keratinocyte by FasL on T cell --> keratinocyte apoptosis Autoimmunity Review 7 (2008) 598-608
  20. 20. FAS/FAS LIGAND ➤ Jurket cell ➤ Express high level of Fas ➤ Highly sensitive to Fas-induced apoptosis Autoimmunity Review 7 (2008) 598-608
  21. 21. FAS/FAS LIGAND ➤ Soluble FasL (sFasL) ➤ Proteolytic processing membrane-bound form of FasL ➤ Level increasing in early but return to baseline levels after progression creases ➤ Not specific for SJS/TEN but also in other drug-induced cutaneous eruption, some inflammatory skin disease and several autoimmune disease ➤ Unclear role Autoimmunity Review 7 (2008) 598-608
  22. 22. FAS/FAS LIGAND ➤ Sera from TEN patients can induce apoptosis in normal human keratinocytes and could be almost completely inhibited by antiFasL mAb ➤ IVIG : blocking Fas activity Autoimmunity Review 7 (2008) 598-608
  23. 23. PERFORIN/GRANZYME B ➤ Blister fluid in TEN ➤ CD8+ lymphocyte ➤ Markers of NK cells or cytotoxic T ➤ Able to lyse autologous keratinocyte in the presence of causative drug Autoimmunity Review 7 (2008) 598-608
  24. 24. PERFORIN/GRANZYME B ➤ Upregulation of MHC class I and induced MHC class II expression ➤ Elevation CD8+ lymphocyte in PBMC and declined to below control levels after systemic high dose conventional treatment ➤ Elevation of mRNA expression of perforin and granzyme B in PBMC : severity of disease Autoimmunity Review 7 (2008) 598-608
  25. 25. PERFORIN/GRANZYME B ➤ Drug-specific CTL ➤ Incresed expression of Perforin and Granzyme B on epidermal CD8 T cell ➤ Induced an influx of CD4+ T cell into epidermis ➤ Keratinocyte apoptosis Autoimmunity Review 7 (2008) 598-608
  26. 26. CYTOKINE DYSREGULATION ➤ Specimen from biopsy : express elevated levels of IFN- gamma, TNF-alpha, IL-5, IL-6, IL-10 and IL-13 ➤ Blister fluid : high concentration of IFN-gamma, TNF-alpha, IL-6, IL-13 and IL-18(induce IFN-gamma) Autoimmunity Review 7 (2008) 598-608
  27. 27. CYTOKINE DYSREGULATION ➤ IFN-gamma, TNF-alpha and IL-1beta along with IL-15 can enhance surface expression of FasL on human keratinocyte ➤ Upregulation adhesion molecules --> recruitment of lymphocyte to the skin ➤ Elabolation of type I cytokine profile ( IFN-gamma and TNF- alpha --> major trigger keratinocyte apoptosis Autoimmunity Review 7 (2008) 598-608
  28. 28. CLINICAL CHARACTERISTICS ➤ Influenza-like symptoms : 1-14 days ➤ Fever ➤ Cough ➤ Myalgias ➤ Arthralgias ➤ Malaise Autoimmunity Review 7 (2008) 598-608
  29. 29. CLINICAL CHARACTERISTICS : SKIN LESION ➤ Flat, irregular, atypical target lesions or diffuse purpuric macules with frequently necrotic center ➤ Mostly trunk and face, also neck and proximal extremities ➤ Positive Nickolsky sign ➤ Reepithelialization usually begins after a few days and complete within 2-3 weeks Autoimmunity Review 7 (2008) 598-608
  30. 30. CLINICAL MANIFESTRATION
  31. 31. SIMILARITIES IN CLINICAL PRESENTATION Journal of Rare Disease 2010 , 5:39 International Journal of Pharmacology Reasearch volume4 Issue4 (2014)
  32. 32. CLINICAL CHARACTERISTICS ➤ Erythematous, painful erosion : Buccal mucosa, ocular and genital mucosa ➤ Ocular involvement ➤ Acute conjunctivitis ➤ Eyelid edema and crusting to conjunctival memebrane or pseudomembrane ➤ Cornea erosions ➤ Cicratizing symblepharon ➤ Conjunctival fornix foreshortening ➤ Corneal ulcer Autoimmunity Review 7 (2008) 598-608
  33. 33. TREATMENT
  34. 34. FOUNDAMENTAL INTERDISCIPLINARY TREATMENT Autoimmunity Review 7 (2008) 598-608
  35. 35. DRUG THERAPY ➤ Intravenous immunoglobulin ➤ Anti-Fas potential of pooled human intravenous immunoglobulin ➤ Suggested dose : more than 2 g/kg ➤ One study showed that each 1 g/kg increase in IVIG = 4.2 fold in TEN patient survival Harr and French Ophanet Journal of Rare Diseases 2010, 5:39
  36. 36. Harr and French Ophanet Journal of Rare Diseases 2010, 5:39
  37. 37. Harr and French Ophanet Journal of Rare Diseases 2010, 5:39
  38. 38. Harr and French Ophanet Journal of Rare Diseases 2010, 5:39
  39. 39. DRUG THERAPY ➤ Systemic steriod : controversy ➤ Thalidomide (anti TNF alpha) : higher mortality ➤ TNF antagonist : infliximab, etanercept ➤ Ciclosporin (CsA) : may be useful ➤ Cyclophosphamide (CPP) ➤ Plasmapheresis/plasma exchange Harr and French Ophanet Journal of Rare Diseases 2010, 5:39
  40. 40. ALLERGOLOGICAL TESTING ➤ Detailed drug history ➤ Patch testing : low sensitivity ➤ Lymphocyte transformation test (LTT) : very low sensitivity ➤ Up regulation of CD69 on T-lymphocytes two days after lymphocyte stimulation in vitro Autoimmunity Review 7 (2008) 598-608
  41. 41. MORTALITY
  42. 42. MORTALITY

×